Anna Maisa1, Anna C Hearps, Thomas A Angelovich, Candida F Pereira, Jingling Zhou, Margaret D Y Shi, Clovis S Palmer, William A Muller, Suzanne M Crowe, Anthony Jaworowski. 1. aCentre for Biomedical Research, Burnet Institute bDepartment of Infectious Diseases, Monash University cSchool of Applied Sciences, RMIT University dMonash Micro Imaging, Monash University eDepartment of Microbiology and Immunology, Melbourne University, Melbourne, Victoria, Australia fFeinberg School of Medicine, Northwestern University, Chicago, Illinois, USA gDepartment of Immunology, Monash University, Melbourne, Victoria, Australia.
Abstract
DESIGN: HIV-infected (HIV+) individuals have an increased risk of atherosclerosis and cardiovascular disease which is independent of antiretroviral therapy and traditional risk factors. Monocytes play a central role in the development of atherosclerosis, and HIV-related chronic inflammation and monocyte activation may contribute to increased atherosclerosis, but the mechanisms are unknown. METHODS: Using an in-vitro model of atherosclerotic plaque formation, we measured the transendothelial migration of purified monocytes from age-matched HIV+ and uninfected donors and examined their differentiation into foam cells. Cholesterol efflux and the expression of cholesterol metabolism genes were also assessed. RESULTS: Monocytes from HIV+ individuals showed increased foam cell formation compared with controls (18.9 vs. 0%, respectively, P = 0.004) and serum from virologically suppressed HIV+ individuals potentiated foam cell formation by monocytes from both uninfected and HIV+ donors. Plasma tumour necrosis factor (TNF) levels were increased in HIV+ vs. control donors (5.9 vs. 3.5 pg/ml, P = 0.02) and foam cell formation was inhibited by blocking antibodies to TNF receptors, suggesting a direct effect on monocyte differentiation to foam cells. Monocytes from virologically suppressed HIV+ donors showed impaired cholesterol efflux and decreased expression of key genes regulating cholesterol metabolism, including the cholesterol transporter ABCA1 (P = 0.02). CONCLUSION: Monocytes from HIV+ individuals show impaired cholesterol efflux and are primed for foam cell formation following transendothelial migration. Factors present in HIV+ serum, including elevated TNF levels, further enhance foam cell formation. The proatherogenic phenotype of monocytes persists in virologically suppressed HIV+ individuals and may contribute mechanistically to increased atherosclerosis in this population.
DESIGN:HIV-infected (HIV+) individuals have an increased risk of atherosclerosis and cardiovascular disease which is independent of antiretroviral therapy and traditional risk factors. Monocytes play a central role in the development of atherosclerosis, and HIV-related chronic inflammation and monocyte activation may contribute to increased atherosclerosis, but the mechanisms are unknown. METHODS: Using an in-vitro model of atherosclerotic plaque formation, we measured the transendothelial migration of purified monocytes from age-matched HIV+ and uninfected donors and examined their differentiation into foam cells. Cholesterol efflux and the expression of cholesterol metabolism genes were also assessed. RESULTS: Monocytes from HIV+ individuals showed increased foam cell formation compared with controls (18.9 vs. 0%, respectively, P = 0.004) and serum from virologically suppressed HIV+ individuals potentiated foam cell formation by monocytes from both uninfected and HIV+ donors. Plasma tumour necrosis factor (TNF) levels were increased in HIV+ vs. control donors (5.9 vs. 3.5 pg/ml, P = 0.02) and foam cell formation was inhibited by blocking antibodies to TNF receptors, suggesting a direct effect on monocyte differentiation to foam cells. Monocytes from virologically suppressed HIV+ donors showed impaired cholesterol efflux and decreased expression of key genes regulating cholesterol metabolism, including the cholesterol transporter ABCA1 (P = 0.02). CONCLUSION: Monocytes from HIV+ individuals show impaired cholesterol efflux and are primed for foam cell formation following transendothelial migration. Factors present in HIV+ serum, including elevated TNF levels, further enhance foam cell formation. The proatherogenic phenotype of monocytes persists in virologically suppressed HIV+ individuals and may contribute mechanistically to increased atherosclerosis in this population.
Authors: A D Raymond; T C Campbell-Sims; M Khan; M Lang; M B Huang; V C Bond; M D Powell Journal: AIDS Res Hum Retroviruses Date: 2010-10-21 Impact factor: 2.205
Authors: A Nakata; Y Nakagawa; M Nishida; S Nozaki; J Miyagawa; T Nakagawa; R Tamura; K Matsumoto; K Kameda-Takemura; S Yamashita; Y Matsuzawa Journal: Arterioscler Thromb Vasc Biol Date: 1999-05 Impact factor: 8.311
Authors: Matthew S Freiberg; Chung-Chou H Chang; Lewis H Kuller; Melissa Skanderson; Elliott Lowy; Kevin L Kraemer; Adeel A Butt; Matthew Bidwell Goetz; David Leaf; Kris Ann Oursler; David Rimland; Maria Rodriguez Barradas; Sheldon Brown; Cynthia Gibert; Kathy McGinnis; Kristina Crothers; Jason Sico; Heidi Crane; Alberta Warner; Stephen Gottlieb; John Gottdiener; Russell P Tracy; Matthew Budoff; Courtney Watson; Kaku A Armah; Donna Doebler; Kendall Bryant; Amy C Justice Journal: JAMA Intern Med Date: 2013-04-22 Impact factor: 21.873
Authors: Eoin R Feeney; Nuala McAuley; Jane A O'Halloran; Clare Rock; Justin Low; Claudette S Satchell; John S Lambert; Gerald J Sheehan; Patrick W G Mallon Journal: J Infect Dis Date: 2012-11-29 Impact factor: 5.226
Authors: Mark A Bernard; Xinbing Han; Sonya Inderbitzin; Ifunanya Agbim; Hui Zhao; Henry Koziel; Souvenir D Tachado Journal: PLoS One Date: 2014-08-04 Impact factor: 3.240
Authors: Michelle L D'Antoni; Brooks I Mitchell; Sara McCurdy; Mary Margaret Byron; Debra Ogata-Arakaki; Dominic Chow; Nehal N Mehta; William A Boisvert; Eric Lefebvre; Cecilia M Shikuma; Lishomwa C Ndhlovu; Yvonne Baumer Journal: J Leukoc Biol Date: 2018-08-08 Impact factor: 4.962
Authors: Thomas A Angelovich; Anna C Hearps; Michael N Oda; Mark S Borja; Diana Huynh; Stefanie Homann; Anthony Jaworowski; Theodoros Kelesidis Journal: AIDS Date: 2017-11-13 Impact factor: 4.632